TScan Therapeutics Files 8-K

TL;DR

TSCN filed an 8-K, likely with operational updates.

AI Summary

TScan Therapeutics, Inc. filed an 8-K on April 8, 2024, to report other events and financial statements. The filing does not contain specific financial figures or details about the 'other events' in the provided text.

Why It Matters

This filing indicates TScan Therapeutics is making a regulatory submission to the SEC, which could contain important updates about the company's operations or financial status.

Risk Assessment

Risk Level: low — The filing is a standard SEC disclosure and does not inherently present new risks without further details.

Key Players & Entities

• TScan Therapeutics, Inc. (company) — Registrant
• April 8, 2024 (date) — Date of Report
• 880 Winter Street (location) — Business Address
• Waltham (location) — City
• MA (location) — State
• 02451 (location) — ZIP Code

FAQ

From the Filing

0001193125-24-089164.txt : 20240408 0001193125-24-089164.hdr.sgml : 20240408 20240408081702 ACCESSION NUMBER: 0001193125-24-089164 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 15 CONFORMED PERIOD OF REPORT: 20240408 ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20240408 DATE AS OF CHANGE: 20240408 FILER: COMPANY DATA: COMPANY CONFORMED NAME: TScan Therapeutics, Inc. CENTRAL INDEX KEY: 0001783328 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 825282075 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-40603 FILM NUMBER: 24828226 BUSINESS ADDRESS: STREET 1: 880 WINTER STREET CITY: WALTHAM STATE: MA ZIP: 02451 BUSINESS PHONE: 857-399-9500 MAIL ADDRESS: STREET 1: 880 WINTER STREET CITY: WALTHAM STATE: MA ZIP: 02451 8-K 1 d810490d8k.htm 8-K 8-K false 0001783328 0001783328 2024-04-08 2024-04-08     UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549     FORM 8-K     CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) April 8, 2024     TSCAN THERAPEUTICS, INC. (Exact name of registrant as specified in its charter)       Delaware   001-40603   82-5282075 (State or other jurisdiction of incorporation)   (Commission File Number)   (I.R.S. Employer Identification No.)   830 Winter Street , Waltham , Massachusetts   02451 (Address of principal executive offices)   (Zip Code) Registrant’s telephone number, including area code (857) 399-9500 Not Applicable (Former name or former address, if changed since last report)     Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:   ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)   ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)   ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))   ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act:   Title of each class   Trade Symbol(s)   Name of each exchange on which registered Voting Common Stock, $0.0001 par value per share   TCRX   The Nasdaq Global Market LLC Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter). Emerging growth company  ☒ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐       Item 8.01. Other Events. On April 8, 2024, TScan Therapeutics, Inc. (the “Company”) issued a press release announcing the appointment of Chrystal U. Louis, M.D., M.P.H., as the Company’s Chief Medical Officer, and the departure of Deborah Barton, M.D., from her position as the Company’s Chief Medical Officer. Dr. Barton is departing the Company for personal reasons and will continue to advise the Company as a consultant to ensure a smooth transition of responsibilities. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.   Item 9.01. Financial Statements and Exhib